Topic: antibiotic resistance
Merck, Novo Holdings and several smaller drug developers are partnering with BIO to spur R&D in the fight against superbugs.
On the heels of its Zerbaxa label expansion last month, Merck scored an FDA nod for an entirely new antibacterial drug combo called Recarbrio.
Amid China's tighter grip on antibiotics use, Lilly sold Chinese rights to two legacy antibiotics and a manufacturing facility to China's Eddingpharm.
Nuzyra, approved for CABP and ABSSSI, represents the first in a new chemical class within tetracycline, with peak sales projected at over $500 million.
McCann Health sees its nascent science brain trust as a way to tackle big, global problems, and last week, in conjunction with the UN General Assembly, it picked its priority issues.
Just as Big Pharmas are bailing out of antibiotics research left and right, a small biotech is pressing ahead with a new drug approval.
India’s Wockhardt has built a $40 million manufacturing facility in the Middle East to make drug-resistant antibiotics.
Achaogen shares slipped Tuesday after the FDA slapped brand-new Zemdri with a black-box warning and nixed a second indication it hoped to gain.
Novasep, which makes clinical supplies for a new antibiotic being developed by Tetraphase, will now start commercial-scale production.
Already reeling from bad news on its dengue shot, Sanofi canned its phase 3 C. diff vaccine—and the $500 million-plus in sales that might have come with it.